Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease
Valérie Fontaine, Elodie Monteiro, Mylène Fournié, Elena Brazhnikova, Thinhinane Boumedine, Cécile Vidal, Christine Balducci, Louis Guibout, Mathilde Latil, Pierre J. Dilda, Stanislas Veillet, José‐Alain Sahel, René Lafont, Serge Camelo
Abstract
mice following the "early curative" supplementation showed optimal neuroprotection and maintenance of photoreceptor function and reduced ocular A2E accumulation. Thus, norbixin appears promising as a systemic drug candidate for both AMD and STGD treatment.
Topics & Concepts
LipofuscinMacular degenerationStargardt diseaseNeuroprotectionMedicineFunction (biology)ChemistryOphthalmologyPharmacologyInternal medicineBiologyCell biologyRetinal Diseases and TreatmentsRetinal Development and DisordersAntioxidant Activity and Oxidative Stress